U.S. clinical study of ASC47 combined with semaglutide for the treatment of obesity completes dosing of subjects
July 16, 2025
Source: drugdu
108
July 15, Ascletis Pharmaceuticals-B (01672.HK) announced on the Hong Kong Stock Exchange that the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) to evaluate the safety, tolerability and preliminary efficacy of a single subcutaneous injection of ultra-long-acting ASC47 combined with semaglutide in obese subjects without type 2 diabetes on day 29 has recently completed dosing of all 28 subjects. The enrollment of the 28 subjects was completed quickly within two months.
"The rapid progress of ASC47 clinical enrollment highlights the industry's strong interest in weight-loss new therapies and the potential benefits of combination therapy," said Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis. "The trial is progressing steadily as planned and is expected to obtain its top-line data in the fourth quarter of 2025."
https://finance.eastmoney.com/a/202507153456982312.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
